tiprankstipranks
Trending News
More News >
Icu Medical (ICUI)
NASDAQ:ICUI
US Market

ICU Medical (ICUI) Earnings Dates, Call Summary & Reports

Compare
205 Followers

Earnings Data

Report Date
May 11, 2026
After Close (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
1.76
Last Year’s EPS
1.72
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 19, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted clear operational progress — record operational quarters, closure of a major FDA warning letter, near-completion of manufacturing and ERP integrations, product roadmap advancement, steady organic growth and disciplined debt reduction. However, material near-term headwinds remain: the deconsolidation of the IV Solutions JV, substantial tariff costs, integration and remediation spend that depressed EBITDA and EPS in the short term, and an underperforming Vital Care segment. Management provided conservative but constructive 2026 guidance and expects improvements in margins and free cash flow as integrations complete and tariff actions/mitigations progress. Overall, the narrative is one of progress toward targets with meaningful but addressable obstacles still weighing on near-term financials.
Company Guidance
ICU Medical guided 2026 to consolidated organic revenue growth of low- to mid-single-digits (consumables and infusion systems each mid-single-digits; Vital Care flat to slightly down), adjusted gross margin around 41% (improving through the year), tariff expense roughly 2% of revenue (the annualized tariff + IV solutions deconsolidation impact ≈ $25M), adjusted operating expense ~25% of revenue (SG&A ~21%, R&D ~4%), adjusted EBITDA $400–$430M, adjusted EPS $7.75–$8.45, net interest ≈ $70M, adjusted tax rate ≈25%, diluted shares ≈25.3M, and free cash flow expected to improve versus 2025’s $100M (FCF weighted to the back half); balance-sheet focus remains debt paydown from any FCF (net debt ≈ $1.0B; debt $1.3B; cash $308M; net leverage just under 2.5x; target ~2.0x by early 2027).
Q4 Revenue and Organic Growth
Q4 revenue of $536 million; total company organic growth of 2% in Q4 and 5% organic growth for full year 2025 (reported -14% in Q4 due to IV Solutions deconsolidation).
Record Operational Quarters
Both consumables and infusion systems delivered record operational revenue quarters in Q4, with consumables Q4 reported growth of 6% (5% organic) and full-year consumables growth of 7% reported / 6% organic.
Adjusted Gross Margin and Profitability
Adjusted gross margin of 40.5% in Q4 (above 40% target). Q4 adjusted EBITDA was $98 million and adjusted EPS was $1.91.
Progress on Regulatory and Product Roadmap
Official closure of the Smiths Medical FDA warning letter; continued progress on 510(k)s for Medfusion 5000 syringe pumps, CADD ambulatory pumps and LifeShield software — supporting a modernized, connected pump portfolio.
Operational Integrations Nearing Completion
Manufacturing integration of two large legacy Smiths Medical sites largely finished; Europe order-to-cash ERP conversion went live; these integrations expected to drive logistics, manufacturing and customer service synergies later in 2026.
Debt Reduction and Strong Cash Generation
Paid down $303 million principal in 2025; ended Q4 with $1.3 billion gross debt and $308 million cash (net debt ~ $1.0 billion); free cash flow of $44 million in Q4 and $100 million for FY2025; net leverage near 2.5x with a goal of 2.0x.
2026 Financial Guidance
Management expects 2026 consolidated organic revenue growth in the low- to mid-single-digit range; adjusted gross margin ~41%; adjusted EBITDA guidance of $400M–$430M and adjusted EPS of $7.75–$8.45; free cash flow expected to improve versus 2025 and be back-weighted to H2.
Product Mix and ASP Tailwind
Back-half 2026 pump unit growth expected to be weighted to higher-ASP Plum Duo and Plum Solo products, which should support revenue and improve hardware gross margin contribution over time.

ICU Medical (ICUI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ICUI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 11, 2026
2026 (Q1)
1.76 / -
1.72
Feb 19, 2026
2025 (Q4)
1.69 / 1.91
2.11-9.48% (-0.20)
Nov 06, 2025
2025 (Q3)
1.43 / 2.03
1.5927.67% (+0.44)
Aug 07, 2025
2025 (Q2)
1.50 / 2.10
1.5634.62% (+0.54)
May 08, 2025
2025 (Q1)
1.28 / 1.72
0.9679.17% (+0.76)
Feb 27, 2025
2024 (Q4)
1.48 / 2.11
1.5734.39% (+0.54)
Nov 12, 2024
2024 (Q3)
1.25 / 1.59
1.571.27% (+0.02)
Aug 07, 2024
2024 (Q2)
1.00 / 1.56
1.88-17.02% (-0.32)
May 07, 2024
2024 (Q1)
0.82 / 0.96
1.74-44.83% (-0.78)
Feb 27, 2024
2023 (Q4)
1.19 / 1.57
1.6-1.88% (-0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ICUI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 19, 2026
$149.74$157.03+4.87%
Nov 06, 2025
$129.67$140.16+8.09%
Aug 07, 2025
$129.91$112.85-13.13%
May 08, 2025
$142.87$138.30-3.20%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Icu Medical (ICUI) report earnings?
Icu Medical (ICUI) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
    What is Icu Medical (ICUI) earnings time?
    Icu Medical (ICUI) earnings time is at May 11, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ICUI EPS forecast?
          ICUI EPS forecast for the fiscal quarter 2026 (Q1) is 1.76.